Scientific Knowledge Exchange on genitourinary cancers
In this Scientific Knowledge Exchange Prof. Dr. Manuela Schmidinger, Medical University of Vienna, and PD Dr. Richard Cathomas, Kantonsspital Graubünden in Chur, talk about the new data in genitourinary cancers.
Video Contents01:00 Overwhelming results on Cytoreductive nephrectomy 03:56 Single-agent immunotherapy in RCC active and less toxic 06:56 Biomarkers: Microbiom remains in the center of interest 09:22 Promising preoperative results with IO in bladder cancer 11:55 Closing remarks
Source: ASCO 2018
According to latest results, cytoreductive nephrectomy seems to be no longer a standard for certain patients in metastatic renal cell carcinoma, although some patient groups still benefit from surgery. In muscle invasive bladder cancer, neoadjuvant phase-II-results with immunotherapy show promising results.
The following abstracts are discussed in this SKE:
CARMENA: Cytoreductive nephrectomy followed by sunitinib versus sunitinib alone in metastatic renal cell carcinoma—Results of a phase III noninferiority trial.
Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (accRCC): Results from cohort A of KEYNOTE-427.
A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in muscle invasive bladder cancer (ABACUS).
Preoperative pembrolizumab (pembro) before radical cystectomy (RC) for muscle-invasive urothelial bladder carcinoma (MIUC): Interim clinical and biomarker findings from the phase 2 PURE-01 study.